Page 14 of articles about vaccine

During 2012 PCV2 variants or mutants (mPCV2) appeared in the USA and were frequently associated with PCV-associated diseases. The possibility of lack of cross-protection of commercial vaccines against mPCV2 is now of major concern.

Reducing piglets mingling in farrowing and nursery facilities was found to delay the infectious process leading to a lower number of early infections. Clustering piglets by litter in small units after weaning also decreased significantly the probability of early infection.

Frequent deaths and cases of disease with typical “diamond-skin” lesions appeared in fattening pigs although they were vaccinated against Erysipelothrix rhusiopathiae.

What further increases profitability in pig production is not minimizing costs, but maximizing revenue.

PCV2 vaccination of the gilts prior to insemination with PCV2 spiked-semen showed a clear decrease of viral load in the gilts as well as a much lower viral excretion that were compatible with foetus protection.

Is the right strategy to get a farm stable, that is, control clinical signs reducing the economic impact of the disease; or should a farm adopt strategies to go “negative”? As for other questions in the epidemiological field, our answer is “it depends”.

The virus is highly resistant in the environment, showing also high resistance to chemical and thermal treatments.

How to administer drugs in order to optimize the speed of action, the efficiency and the financial cost.

Might be there is a little doubt nowadays on the beneficial clinical and economic effects of PCV2 vaccination in subclinical infections in piglets, but… which is the role that sows play in the whole picture?